VI
Vineet Laboratories Ltd (VINEETLAB)
₹37.45
Mkt cap
₹71 Cr
P/E ratio
63.60
P/B
1.57
Div yield
0.00%
ROE
3.68%
ROCE
8.49%
EPS (TTM)
₹0.59
Book value
₹24
52W range
28–44
Sector
Healthcare
Price history
Previous close
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
NSE VINEETLABBSE 543298
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
−13.91% from high₹37
₹28+33.94% from low₹44
Current
₹37.45
Prev close
₹36.50
Day
+2.60%
Price performance
1D
+3.01%
1W
+4.71%
1M
+1.79%
3M
+16.73%
6M
+16.44%
1Y
+5.56%
YTD
+8.83%
Financials
Revenue, profit & margin
P/E ratio
63.6×
VINEETLAB is 84% above the sector median of 34.6×
VINEETLAB63.6×
Sector median34.6×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57.20 | 37.52 | 43.37 | 32.65 | 37.05 | 23.86 | 18.96 | 18.10 | 14.08 | 7.44 | 17.42 | 15.65 | 18.89 | |
| Expenses | 51.39 | 37.26 | 39.20 | 33.29 | 33.63 | 24.65 | 19.27 | 22.23 | 25.12 | 7.13 | 14.24 | 13.17 | 16.40 | |
| Operating Profit | 5.81 | 0.26 | 4.17 | -0.64 | 3.42 | -0.79 | -0.31 | -4.13 | -11.04 | 0.31 | 3.18 | 2.48 | 2.49 | |
| OPM % | 10.16% | 0.69% | 9.61% | -1.96% | 9.23% | -3.31% | -1.64% | -22.82% | -78.41% | 4.17% | 18.25% | 15.85% | 13.18% | |
| Other Income | 0.03 | 0.03 | 0.01 | 0.01 | 0.41 | 0.37 | 0.20 | 0.03 | 1.38 | 0.02 | 0.01 | 0.05 | 0.03 | |
| Interest | 0.37 | 0.96 | 1.02 | 1.08 | 1.72 | 1.14 | 0.99 | 0.95 | 0.90 | 0.61 | 2.19 | 1.09 | 0.99 | |
| Depreciation | 0.62 | 0.61 | 0.61 | 0.63 | 0.67 | 0.61 | 0.62 | 0.62 | 0.66 | 0.63 | 0.63 | 0.63 | 0.54 | |
| Profit before tax | 4.85 | -1.28 | 2.55 | -2.34 | 1.44 | -2.17 | -1.72 | -5.67 | -11.22 | -0.91 | 0.37 | 0.81 | 0.99 | |
| Tax % | 26.80% | -2.34% | 4.71% | -11.11% | -34.03% | -1.84% | 6.98% | 0.53% | -6.24% | -4.40% | -8.11% | -3.70% | 27.27% | |
| Net Profit | 3.55 | -1.25 | 2.42 | -2.07 | 1.92 | -2.13 | -1.83 | -5.71 | -10.53 | -0.87 | 0.40 | 0.85 | 0.73 | |
| EPS in Rs | 1.85 | -0.65 | 1.26 | -1.08 | 1.00 | -1.11 | -0.95 | -2.97 | -5.48 | -0.45 | 0.21 | 0.44 | 0.38 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.23% · closed higher next day 1 of last 1
| Q4FY26 | |
|---|---|
| Broadcast | 26 Aug '26 |
| Earnings day | +0.23% |
| +1 day | +0.80% |
| +5 days | −2.92% |
| +15 days | −7.05% |
| +30 days | −2.84% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 20265.98%Promoter
Promoters5.98%
FIIs0.50%0.14
Public93.52%0.15
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Vineet Laborator | ₹36.78 | 63.64 | 71 | 0.00% | 1 | +106.93% | 19 | +34.16% | 8.49% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports5
Announcements5
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Grant Of Extension Of Time By The Registrar Of Companies For Holding The 10St Annual General Meeting Of The Company 19 Sep - ROC Hyderabad grants two-month extension to hold Vineet Laboratories' 10th AGM by 30 November 2026.Results-Delay in Financial Results 29 Aug - Board approved FY26 audited results on August 25, 2026; typo corrected in approval date.Results-Delay in Financial Results 25 AugBoard Meeting Outcome for Outcome Of Board Meeting Held On Tuesday, August 25, 2026 As Required Under Regulation 30 Of SEBI (LODR) Regulations, 2015 25 Aug - Approved audited FY26 results; Q4 profit Rs72.51 lakh, annual profit Rs111.08 lakh, unmodified audit opinion.Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations, 2015. 20 Aug - Board meets on 25 August 2026 to approve audited standalone FY2026 results.